Tirzepatide

Also known as · LY3298176 · Mounjaro · Zepbound · Dual GIP/GLP-1 receptor agonist

Form
Lyophilized powder
Purity
≥98% (HPLC)
Molecular formula
C225H348N48O68
Molecular weight
4813.5 g/mol
CAS number
2023788-19-2
Sequence
39-residue lipidated peptide (Aib, C20 acyl side chain)
COA
Available on request

In stock

Request pricing

Contact us for current pricing and bulk quotes.

Reserve vial →

For research use only. Not for human consumption. Buyers must be affiliated with a research institution.

01 / Research summary

What the literature reports

Tirzepatide (LY3298176) is an FDA-approved 39-residue lipidated peptide sold as Mounjaro (type 2 diabetes) and Zepbound (obesity). It is a dual agonist of the GIP and GLP-1 receptors.

Cellaire classifies Tirzepatide as FDA-approved. The FDA Mounjaro label indicates it as an adjunct to diet and exercise for glycemic control in type 2 diabetes, dosed subcutaneously once weekly starting at 2.5 mg, escalating in 2.5 mg increments after ≥4 weeks to a maximum of 15 mg. The label carries a boxed warning for thyroid C-cell tumors observed in rats.

02 / Reconstitution

Reconstitution reference

Illustrative unit math for a 20 mg vial reconstituted with 2 mL bacteriostatic water. This is not a dose recommendation.

Vial20 mg
BAC water2 mL
Concentration10 mg/mL
Example unit math2.5 mg
On a U-100 syringe25 units on U-100
Open the reconstitution calculator →

03 / Overview

Molecular overview

Tirzepatide is a 39-residue peptide with Aib substitutions at positions 2 and 13 and a C20 fatty-diacid on Lys20. The C-terminus is a serinamide.

The C20 acyl chain binds circulating albumin, extending the plasma half-life to roughly 5 days and supporting once-weekly dosing.

As a dual GIP/GLP-1 agonist, tirzepatide activates two incretin receptors simultaneously. The label documents dose-dependent HbA1c and body-weight reductions in phase-3 SURPASS and SURMOUNT trials.

The FDA declared the tirzepatide shortage resolved in October 2024, closing the 503A compounding pathway. Tirzepatide is a prescription drug and cannot legally be sold as a research chemical for human use.

04 / References

References

  1. FDA Mounjaro (tirzepatide) prescribing information ↗
  2. KEGG DRUG D11360 — Tirzepatide ↗
  3. PubChem — Tirzepatide (CID 166567236) ↗